Joint Discomfort
Conditions
Keywords
Native Collagen, Joint, Joint Discomfort
Brief summary
This study evaluates the effects of 40 mg of b-2Cool, a food supplement rich in native type-II collagen, on healthy adults with joint discomfort. Half of the participants will receive the b-2Cool containing supplement while the other half will receive a placebo pill.
Detailed description
Previous studies had shown the efficacy of the intake of native collagen to relieve pain in healthy patients with joint discomfort. Native collagen is detected in the gut's Peyer's patches and, thanks to a mechanism known as oral tolerisation, reduces the autoimmune attack to joints' collagen improving joint function and pain. Oral tolerance consists of two phases of immune response: the maintenance of homeostasis and the suppression of immune responses mediated by Ag-specific regulatory T cells. T-cells detect the epitopes of type-II collagen in the gut and suppress the immune response against bodily type-II collagen. Then, these regulatory T cells generated in the gut are presumed to migrate to a local microenvironment where a protein analogous to the orally dosed antigen resides, in this case type-II collagen. Upon reactivation in a new microenvironment, regulatory cells will suppress ongoing inflammation.
Interventions
DIETARY_SUPPLEMENTb-2Cool
b-2Cool® is native type II collagen extracted from chicken sternums
OTHERPlacebo
Excipients only
Sponsors
Bioiberica
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
40 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Adults between 40 and 75 years old. * Subject who suffers mild joint discomfort (value between 3 and 5 VAS scale for a minimum of 6 months). * Subject that after reading and understanding the study's protocol has provided written informed consent to participate in the study. * Subjects willing to keep stable eating and activity patterns during the duration of the study. * Subjects who use other therapies for joint discomfort, such as exercise, heat / cold, joint protection and physiotherapy / occupational therapy agree to follow the treatments avoiding changes in the frequency or intensity of them and reporting them at baseline and during follow-ups. * Subjects agree not start any new therapy during the study period. * Subjects who have lateral or longitudinal knee synovial effusion according to the index OMERACT (Outcome Measures in Rheumatology) .
Exclusion criteria
* Active rheumatoid arthritis, diagnosed osteoarthritis or any other inflammatory arthritic condition that researchers consider non appropriate. * Being pregnant or lactating. * Be waiting for joint surgery or major surgery in the next 8 months * Joint injury in the last 4 months in the area osteoarthritis-affected (i.e. meniscal tear) * Having underwent reconstructive surgery on the cartilage of the affected knee * Background of peptidic ulcer and other symptomatic/active disorders of the intestinal tract that may interfere with product under evaluation . * History of congestive heart failure, * Allergy to chicken or other ingredients in the product * Anticipated problems with product consumption * High alcohol consumption (\> 2 drinks per day) * History of psychiatric disorders that may impede the ability of subjects to give written informed consent * Failure to comply with washout periods before the start of the study. * Paracetamol intake 24 hours before randomization * The subject does not want to stop taking medication in addition to the study medication (for arthritis or other pain) or not to take other types of medication for the treatment of osteoarthritis pain * Other conditions that, in the opinion of the principal investigator adversely affect the subject's ability to complete the study or its measures
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change from baseline of ultrasonographic assessment of synovial effusion | 0, 6, 12 and 24 weeks |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| WOMAC Functional assesment | 0, 6, 12 and 24 weeks | — |
| Subjective evaluation of quality of life | 0, 6, 12 and 24 weeks | Patients will report some aspects of their Quality of life through Visual analogic scales |
| Collagen degradation markers in urine | 0, 12 and 24 weeks | — |
| Visual Analog Scale (VAS) pain evaluation | 0, 6, 12 and 24 weeks | — |
| Rescue medication consumption | Every 2 weeks for 24 weeks | — |
| Adverse events | 6 months | — |
| Patient's satisfaction | 6, 12 and 24 weeks | Patient satisfaction will be evaluated using a subjective questionnaire |
Outcome results
None listed